Palisade Bio (NASDAQ:PALI) Upgraded by LADENBURG THALM/SH SH to Strong-Buy Rating

Palisade Bio (NASDAQ:PALI) was upgraded by analysts at LADENBURG THALM/SH SH to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

Other analysts have also recently issued research reports about the company. HC Wainwright assumed coverage on Palisade Bio in a research report on Thursday, March 26th. They issued a “buy” rating and a $7.00 price objective for the company. Wolfe Research assumed coverage on Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 target price on the stock. Stifel Nicolaus initiated coverage on Palisade Bio in a research note on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target for the company. Wall Street Zen downgraded Palisade Bio from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings lowered Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 9th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $10.20.

Palisade Bio Stock Up 5.0%

NASDAQ:PALI opened at $1.89 on Thursday. The stock has a market capitalization of $328.07 million, a price-to-earnings ratio of -1.87 and a beta of 1.52. Palisade Bio has a 52 week low of $0.53 and a 52 week high of $2.85. The firm has a 50 day moving average of $1.95 and a 200 day moving average of $1.91.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). As a group, analysts expect that Palisade Bio will post -0.21 EPS for the current year.

Institutional Investors Weigh In On Palisade Bio

A number of large investors have recently made changes to their positions in the stock. Cetera Investment Advisers acquired a new position in shares of Palisade Bio in the 4th quarter valued at $25,000. Schonfeld Strategic Advisors LLC purchased a new position in Palisade Bio in the 4th quarter worth $26,000. Virtu Financial LLC acquired a new stake in Palisade Bio during the 4th quarter worth about $28,000. CTC Alternative Strategies Ltd. acquired a new stake in Palisade Bio during the 1st quarter worth about $31,000. Finally, Atom Investors LP purchased a new stake in Palisade Bio during the 4th quarter valued at about $33,000. 11.79% of the stock is owned by hedge funds and other institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.